Active Primary Sjogren’s

Clinical Research Institute of Michigan – Shores Rheumatology
Main: 586-598-3329
Study Coordinator: Amelia Laurence 586-598-3329 X 201
Study Coordinator: Latrece Keaton 586-598-3329 X 202

  • Indication: Psoriatic Arthritis
  • Enrollment Status: Open
  • Protocol: RC18G007
  • Drug: telitacicept
  • Sponsor: VorBio
  • Description: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren’s Disease

Returning Member? Please login to check membership status!